source
- Artelo’s oral cannabinoid agonist matches semaglutide weight loss in obese mice, doubles effect when combinedArtelo Biosciences reported that its oral dual cannabinoid agonist, ART27.13, produced weight loss in diet‑induced obese mice that was comparable to the GLP‑1 receptor agonist semaglutide. In a fo…
- Clinical trial enrollment crisis threatens billions in revenue and patient accessClinical trials are struggling with enrollment, with about 80% missing timelines and less than 5% of eligible adult cancer patients participating. Delays have huge financial impact; each day a pha…